Exact Mass: 1049.5433

Exact Mass Matches: 1049.5433

Found 24 metabolites which its exact mass value is equals to given mass value 1049.5433, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

CDP-DG(a-17:0/20:3(8Z,11Z,14Z)-2OH(5,6))

{[(2R,3S,4R,5R)-3,4-dihydroxy-5-(2-hydroxy-4-imino-1,4-dihydropyrimidin-1-yl)oxolan-2-yl]methoxy}({[(2R)-2-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-3-[(14-methylhexadecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)phosphinate

C49H85N3O17P2 (1049.5354)


CDP-DG(a-17:0/20:3(8Z,11Z,14Z)-2OH(5,6)) is an oxidized CDP-diacylglycerol (CDP-DG). Oxidized CDP-diacylglycerols are glycerophospholipids in which a cytidine diphosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized CDP-diacylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. CDP-DG(a-17:0/20:3(8Z,11Z,14Z)-2OH(5,6)), in particular, consists of one chain of one 14-methylhexadecanoyl at the C-1 position and one chain of 5,6-dihydroxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized CDP-DGs can be synthesized via three different routes. In one route, the oxidized CDP-DG is synthetized de novo following the same mechanisms as for CDP-DGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the CDP-DG backbone, mainly through the action of LOX (PMID: 33329396).

   

CDP-DG(20:3(8Z,11Z,14Z)-2OH(5,6)/a-17:0)

{[(2R,3S,4R,5R)-3,4-dihydroxy-5-(2-hydroxy-4-imino-1,4-dihydropyrimidin-1-yl)oxolan-2-yl]methoxy}({[(2R)-3-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-2-[(14-methylhexadecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)phosphinate

C49H85N3O17P2 (1049.5354)


CDP-DG(20:3(8Z,11Z,14Z)-2OH(5,6)/a-17:0) is an oxidized CDP-diacylglycerol (CDP-DG). Oxidized CDP-diacylglycerols are glycerophospholipids in which a cytidine diphosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized CDP-diacylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. CDP-DG(20:3(8Z,11Z,14Z)-2OH(5,6)/a-17:0), in particular, consists of one chain of one 5,6-dihydroxyeicosatrienoyl at the C-1 position and one chain of 14-methylhexadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized CDP-DGs can be synthesized via three different routes. In one route, the oxidized CDP-DG is synthetized de novo following the same mechanisms as for CDP-DGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the CDP-DG backbone, mainly through the action of LOX (PMID: 33329396).

   

CDP-DG(i-17:0/20:3(8Z,11Z,14Z)-2OH(5,6))

{[(2R,3S,4R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}({[(2R)-2-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-3-[(15-methylhexadecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)phosphinic acid

C49H85N3O17P2 (1049.5354)


CDP-DG(i-17:0/20:3(8Z,11Z,14Z)-2OH(5,6)) is an oxidized CDP-diacylglycerol (CDP-DG). Oxidized CDP-diacylglycerols are glycerophospholipids in which a cytidine diphosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized CDP-diacylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. CDP-DG(i-17:0/20:3(8Z,11Z,14Z)-2OH(5,6)), in particular, consists of one chain of one 15-methylhexadecanoyl at the C-1 position and one chain of 5,6-dihydroxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized CDP-DGs can be synthesized via three different routes. In one route, the oxidized CDP-DG is synthetized de novo following the same mechanisms as for CDP-DGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the CDP-DG backbone, mainly through the action of LOX (PMID: 33329396).

   

CDP-DG(20:3(8Z,11Z,14Z)-2OH(5,6)/i-17:0)

{[(2R,3S,4R,5R)-3,4-dihydroxy-5-(2-hydroxy-4-imino-1,4-dihydropyrimidin-1-yl)oxolan-2-yl]methoxy}({[(2R)-3-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-2-[(15-methylhexadecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)phosphinate

C49H85N3O17P2 (1049.5354)


CDP-DG(20:3(8Z,11Z,14Z)-2OH(5,6)/i-17:0) is an oxidized CDP-diacylglycerol (CDP-DG). Oxidized CDP-diacylglycerols are glycerophospholipids in which a cytidine diphosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized CDP-diacylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. CDP-DG(20:3(8Z,11Z,14Z)-2OH(5,6)/i-17:0), in particular, consists of one chain of one 5,6-dihydroxyeicosatrienoyl at the C-1 position and one chain of 15-methylhexadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized CDP-DGs can be synthesized via three different routes. In one route, the oxidized CDP-DG is synthetized de novo following the same mechanisms as for CDP-DGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the CDP-DG backbone, mainly through the action of LOX (PMID: 33329396).

   
   
   

gagaminin 3-O-alpha-L-cymaropyranosyl-(1->4)-beta-D-cymaropyranosyl-(1->4)-beta-D-cymaropyranoside

gagaminin 3-O-alpha-L-cymaropyranosyl-(1->4)-beta-D-cymaropyranosyl-(1->4)-beta-D-cymaropyranoside

C57H79NO17 (1049.5348)


   

(Lycoperoside H) FA or (Hydroxy-α-Tomatine) FA III

(Lycoperoside H) FA or (Hydroxy-α-Tomatine) FA III

C50H83NO22 (1049.5406)


   

(Lycoperoside H) FA or (Hydroxy-α-Tomatine) FA II

(Lycoperoside H) FA or (Hydroxy-α-Tomatine) FA II

C50H83NO22 (1049.5406)


   
   

(Lycoperoside H) FA or (Hydroxy-α-Tomatine) FA I

(Lycoperoside H) FA or (Hydroxy-α-Tomatine) FA I

C50H83NO22 (1049.5406)


   

Solasodine base + 2H, 1O, O-Hex-Hex-Hex-Pen

Solasodine base + 2H, 1O, O-Hex-Hex-Hex-Pen

C50H83NO22 (1049.5406)


Annotation level-3

   

(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-acetamidoacetyl)amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]propanoyl]amino]-6-aminohexanoic acid

(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-acetamidoacetyl)amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]propanoyl]amino]-6-aminohexanoic acid

C46H75N13O15 (1049.5505)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C129821 - Antineoplastic Biological Agent C307 - Biological Agent

   

CDP-DG(a-17:0/20:3(8Z,11Z,14Z)-2OH(5,6))

CDP-DG(a-17:0/20:3(8Z,11Z,14Z)-2OH(5,6))

C49H85N3O17P2 (1049.5354)


   

CDP-DG(20:3(8Z,11Z,14Z)-2OH(5,6)/a-17:0)

CDP-DG(20:3(8Z,11Z,14Z)-2OH(5,6)/a-17:0)

C49H85N3O17P2 (1049.5354)


   

CDP-DG(i-17:0/20:3(8Z,11Z,14Z)-2OH(5,6))

CDP-DG(i-17:0/20:3(8Z,11Z,14Z)-2OH(5,6))

C49H85N3O17P2 (1049.5354)


   

CDP-DG(20:3(8Z,11Z,14Z)-2OH(5,6)/i-17:0)

CDP-DG(20:3(8Z,11Z,14Z)-2OH(5,6)/i-17:0)

C49H85N3O17P2 (1049.5354)


   

(1s)-1-[(1s,3ar,3bs,7s,9ar,9br,11r,11ar)-1,3a,3b-trihydroxy-7-{[(2r,4s,5r,6r)-5-{[(2s,4s,5r,6r)-5-{[(2s,4r,5s,6s)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-9a,11a-dimethyl-11-{[(2e)-3-phenylprop-2-enoyl]oxy}-2h,3h,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl pyridine-3-carboxylate

(1s)-1-[(1s,3ar,3bs,7s,9ar,9br,11r,11ar)-1,3a,3b-trihydroxy-7-{[(2r,4s,5r,6r)-5-{[(2s,4s,5r,6r)-5-{[(2s,4r,5s,6s)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-9a,11a-dimethyl-11-{[(2e)-3-phenylprop-2-enoyl]oxy}-2h,3h,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl pyridine-3-carboxylate

C57H79NO17 (1049.5348)


   

2-[(2-{[4,5-dihydroxy-6-({22-hydroxy-10,14,16,20-tetramethyl-23-oxa-18-azahexacyclo[12.11.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²⁴.0¹⁷,²²]pentacosan-7-yl}oxy)-2-(hydroxymethyl)oxan-3-yl]oxy}-5-hydroxy-6-(hydroxymethyl)-4-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol

2-[(2-{[4,5-dihydroxy-6-({22-hydroxy-10,14,16,20-tetramethyl-23-oxa-18-azahexacyclo[12.11.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²⁴.0¹⁷,²²]pentacosan-7-yl}oxy)-2-(hydroxymethyl)oxan-3-yl]oxy}-5-hydroxy-6-(hydroxymethyl)-4-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C50H83NO22 (1049.5406)


   

1-(1,3a,3b-trihydroxy-7-{[5-({5-[(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-4-methoxy-6-methyloxan-2-yl}oxy)-4-methoxy-6-methyloxan-2-yl]oxy}-9a,11a-dimethyl-11-[(3-phenylprop-2-enoyl)oxy]-2h,3h,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl)ethyl pyridine-3-carboxylate

1-(1,3a,3b-trihydroxy-7-{[5-({5-[(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-4-methoxy-6-methyloxan-2-yl}oxy)-4-methoxy-6-methyloxan-2-yl]oxy}-9a,11a-dimethyl-11-[(3-phenylprop-2-enoyl)oxy]-2h,3h,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl)ethyl pyridine-3-carboxylate

C57H79NO17 (1049.5348)


   

(2z)-n-[(3s,6s,9e,12s,23s,26r,27s,30s,32r)-20-benzyl-6-[(2s)-butan-2-yl]-9-ethylidene-5,8,11,22,25,32-hexahydroxy-3-[2-(c-hydroxycarbonimidoyl)ethyl]-23-(methoxymethyl)-18,27-dimethyl-2,17,19,29-tetraoxo-28-oxa-1,4,7,10,16,21,24-heptaazatricyclo[28.3.0.0¹²,¹⁶]tritriaconta-4,7,10,21,24-pentaen-26-yl]-2-methylhex-2-enimidic acid

(2z)-n-[(3s,6s,9e,12s,23s,26r,27s,30s,32r)-20-benzyl-6-[(2s)-butan-2-yl]-9-ethylidene-5,8,11,22,25,32-hexahydroxy-3-[2-(c-hydroxycarbonimidoyl)ethyl]-23-(methoxymethyl)-18,27-dimethyl-2,17,19,29-tetraoxo-28-oxa-1,4,7,10,16,21,24-heptaazatricyclo[28.3.0.0¹²,¹⁶]tritriaconta-4,7,10,21,24-pentaen-26-yl]-2-methylhex-2-enimidic acid

C52H75N9O14 (1049.5433)


   

(1s)-1-[(1s,3ar,3bs,7s,9ar,9br,11r,11ar)-1,3a,3b-trihydroxy-7-{[(2r,4s,5r,6r)-5-{[(2s,4r,5r,6r)-5-{[(2s,4r,5s,6s)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-9a,11a-dimethyl-11-{[(2e)-3-phenylprop-2-enoyl]oxy}-2h,3h,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl pyridine-3-carboxylate

(1s)-1-[(1s,3ar,3bs,7s,9ar,9br,11r,11ar)-1,3a,3b-trihydroxy-7-{[(2r,4s,5r,6r)-5-{[(2s,4r,5r,6r)-5-{[(2s,4r,5s,6s)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-9a,11a-dimethyl-11-{[(2e)-3-phenylprop-2-enoyl]oxy}-2h,3h,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl pyridine-3-carboxylate

C57H79NO17 (1049.5348)


   

(1s)-1-[(1s,3ar,3bs,7s,9ar,9br,11r,11ar)-1,3a,3b-trihydroxy-7-{[(2r,4s,5r,6r)-5-{[(2s,4s,5r,6r)-5-{[(2s,4r,5r,6r)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-9a,11a-dimethyl-11-{[(2e)-3-phenylprop-2-enoyl]oxy}-2h,3h,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl pyridine-3-carboxylate

(1s)-1-[(1s,3ar,3bs,7s,9ar,9br,11r,11ar)-1,3a,3b-trihydroxy-7-{[(2r,4s,5r,6r)-5-{[(2s,4s,5r,6r)-5-{[(2s,4r,5r,6r)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-9a,11a-dimethyl-11-{[(2e)-3-phenylprop-2-enoyl]oxy}-2h,3h,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl pyridine-3-carboxylate

C57H79NO17 (1049.5348)


   

(1s)-1-[(1s,3ar,3bs,7s,9ar,9br,11r,11ar)-1,3a,3b-trihydroxy-7-{[(2r,4s,5r,6r)-5-{[(2s,4r,5r,6r)-5-{[(2s,4r,5r,6r)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-9a,11a-dimethyl-11-{[(2e)-3-phenylprop-2-enoyl]oxy}-2h,3h,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl pyridine-3-carboxylate

(1s)-1-[(1s,3ar,3bs,7s,9ar,9br,11r,11ar)-1,3a,3b-trihydroxy-7-{[(2r,4s,5r,6r)-5-{[(2s,4r,5r,6r)-5-{[(2s,4r,5r,6r)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-9a,11a-dimethyl-11-{[(2e)-3-phenylprop-2-enoyl]oxy}-2h,3h,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl pyridine-3-carboxylate

C57H79NO17 (1049.5348)